Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba
Pure Sunfarms remains top-selling dried cannabis brand with
Pure Sunfarms’ products are now available in five of Canada’s six most populous provinces, representing more than 70% of the Canadian population. Manitoba ranks as the sixth largest Canadian province by cannabis sales, comprising approximately 4.5% of the country’s total sales and has a higher per capita spend on cannabis than the country average2.
“We are thrilled to further expand our presence in
In addition, the Pure Sunfarms brand achieved record sales (defined as sales of Pure Sunfarms products by provincial boards to retailers, as well as sales by provincial boards directly to consumers via their web sites) in
Pure Sunfarms is preparing to launch its first bottled oil and vape products in the coming weeks and continues to advance discussions with other provincial distributors for potential supply agreements to further expand its presence in the Canadian cannabis market.
1. Dried cannabis, by kilograms sold, for the year to date period ended
2. 12 months ended
Please visit www.emeraldhealth.ca for more information or contact:
(800) 757 3536 Ext. #5
Emerald Investor Relations
(800) 757 3536 Ext. #5
Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.
We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.
Source: Emerald Health Therapeutics, Inc.